1.1 Mastisan-E is an integrated drug containing such components as erythromycin, sulfadimezin, beeswax suspended in vegetable oil. One dose (5 ml) of the drug contains 112.5 mg erythromycin and 0.4 g sulfadimezin

1.2 Mastisan-E is a homogeneous oily suspension with white to cream color segregating during storage.

1.3 The drug is prepackaged in glass vials by 100.0 and 200.0 ml or tubes by 5 to 20 ml.

1.4 The drug should be stored with caution (see List B ) in a dry, dark place and kept out of the reach of children within the temperature range from 0ºC to +20ºC. Shelf life is 18 months under specified storage conditions.

2.1 The drug affects many Gram-positive and Gram-negative microorganisms and prevents development of antibiotic-resistant forms of microorganisms and promotes udder tissue regeneration.


3.1 The drug is prescribed for treatment of various forms of udder inflammation and traumatic lesions of the udder and teats skin.

3.2 Before drug introducing the affected quarter of udder shall be eased and teat shall be disinfected. Content of the vial or tube shall be heated up to 36-39 °C and thoroughly stirred until its content becomes uniform and injected into the affected quarter of udder via streak canal by elastic plastic catheter that shall be screwed onto the tube with drug or put on syringe adapter. After injection affected teat of the udder quarter shall be lightly massaged upwards.

3.3 Depending on severity of inflammatory process 5 to 10 ml of drug shall be injected. If required introduction of the drug shall be repeated in lactating cows every 12 hours and in non-milking cows - every 24 hours.

3.4 The course of treatment shall be 2-3 days. If required the treatment shall be repeated until absolute recovery.

3.5 Treatment of traumatic lesions of skin and mucous membranes of the udder teats shall be carried out by application of drug to the affected surface.

3.6 Adverse effects. Allergic responses are noted in rare cases.

3.7 Individual sensitivity to the drug components serve as contraindication to the drug application.

3.8 During the period of treatment milk from affected parts of udder shall be eased into separate containers then sterilized and disposed. Milk from the remaining quarters of udder after boiling shall be used as animal feed. The milk obtained from affected quarters of udder treated by Mastisan-E drug shall be used for human consumption 5 days after treatment subject to complete disappearance of all clinical symptoms of mastitis (acquisition of normal properties of milk by color test and sedimentation test). Meat of animals slaughtered during treatment can be used without restrictions except for udder which is disposed.


4.1 In case of inconsistency of the drug with requirements of this Instruction, its use should be discontinued and reported to the Uzbek State Scientific and Veterinary Drugs Control Laboratory at: 700178, Tashkent, No.1a, A.Yunusov Street. Tel. / Fax: 228-76-14, 229-30 - 47. E-mail: uzgnkl@rambler.ru. Simultaneously unpacked drug package should be sent to the laboratory address with the drug in quantity previously agreed with laboratory including detailed description of the nature of complaints regarding its inconsistency with this Instruction.